Lv11
20 积分 2024-11-17 加入
Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study
4小时前
待确认
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
6小时前
已完结
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
7个月前
已完结
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
7个月前
已完结
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
7个月前
已完结
Understanding national guidelines for infant abduction prevention and response
7个月前
已关闭
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
7个月前
已完结
Linkage between Psychological Factors and Response to Immune Checkpoint Inhibitor Therapy: A Preliminary Study
8个月前
已完结
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
9个月前
已完结
皖公网安备34019202002308
